REGULATORY

Council OKs Public Knowledge Application for CellCept Label Expansion

By Sakura Kono February 3, 2025

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

A health ministry council on January 30 agreed that an application based on information in the public domain would be appropriate for Chugai Pharmaceutical's CellCept (mycophenolate mofetil) for an additional indication of nephrotic syndrome. The Council on Unapproved Drugs and…

To read the full story

CellCept Now Covered for Nephrotic Syndrome: MHLW
March 13, 2025

REGULATORY

Japan Selects JN.1 Substrains for COVID Vaccines in 2026-2027 Season
May 27, 2026
Ex-Minister Kato Preparing Parliamentary Group on Diabetes Issues
May 27, 2026
LDP Lawmakers’ League Urges Economic Efficiency in Drug Use
May 27, 2026
LDP Panel OKs Immunization Act Bill Aimed at Beyfortus NIP Use
May 27, 2026
US Calls Out Japan’s Market Expansion Re-Pricing Rules as “Unfair”: IP Report
May 26, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Are Technical Discussions Enough for Japan’s CEA System?

By Ken Yoshino

Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…